Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The aim is to introduce a new therapeutic method of intracavitary chemotherapy (cisplatin)
combined with a fibrin carrier (Vivostat®) after pleurectomy/decortication or extrapleural
pneumonectomy in a phase I and II study for Malignant Pleural Mesothelioma patients by
evaluation of the safety in a dose-escalating model (phase I), and confirmation of safety
and efficacy in phase II with the maximum tolerated dose in phase I.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Zurich
Collaborators:
Swiss Accident Insurance Fund SUVA Swiss National Science Foundation